Cargando…

Antitumor Activity of a Novel Tyrosine Kinase Inhibitor AIU2001 Due to Abrogation of the DNA Damage Repair in Non-Small Cell Lung Cancer Cells

Class III receptor tyrosine kinase (RTK) inhibitors targeting mainly FLT3 or c-KIT have not been well studied in lung cancer. To identify a small molecule potentially targeting class III RTK, we synthesized novel small molecule compounds and identified 5-(4-bromophenyl)-N-(naphthalen-1-yl) oxazol-2-...

Descripción completa

Detalles Bibliográficos
Autores principales: Ryu, Hwani, Choi, Hyun-Kyung, Kim, Hyo Jeong, Kim, Ah-Young, Song, Jie-Young, Hwang, Sang-Gu, Kim, Jae-Sung, Kim, Da-Un, Kim, Eun-Ho, Kim, Joon, Ahn, Jiyeon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6801739/
https://www.ncbi.nlm.nih.gov/pubmed/31554189
http://dx.doi.org/10.3390/ijms20194728
_version_ 1783460647602749440
author Ryu, Hwani
Choi, Hyun-Kyung
Kim, Hyo Jeong
Kim, Ah-Young
Song, Jie-Young
Hwang, Sang-Gu
Kim, Jae-Sung
Kim, Da-Un
Kim, Eun-Ho
Kim, Joon
Ahn, Jiyeon
author_facet Ryu, Hwani
Choi, Hyun-Kyung
Kim, Hyo Jeong
Kim, Ah-Young
Song, Jie-Young
Hwang, Sang-Gu
Kim, Jae-Sung
Kim, Da-Un
Kim, Eun-Ho
Kim, Joon
Ahn, Jiyeon
author_sort Ryu, Hwani
collection PubMed
description Class III receptor tyrosine kinase (RTK) inhibitors targeting mainly FLT3 or c-KIT have not been well studied in lung cancer. To identify a small molecule potentially targeting class III RTK, we synthesized novel small molecule compounds and identified 5-(4-bromophenyl)-N-(naphthalen-1-yl) oxazol-2-amine (AIU2001) as a novel class III RKT inhibitor. In an in vitro kinase profiling assay, AIU2001 inhibited the activities of FLT3, mutated FLT3, FLT4, and c-KIT of class III RTK, and the proliferation of NSCLC cells in vitro and in vivo. AIU2001 induced DNA damage, reactive oxygen species (ROS) generation, and cell cycle arrest in the G2/M phase. Furthermore, AIU2001 suppressed the DNA damage repair genes, resulting in the ‘BRCAness’/‘DNA-PKness’ phenotype. The mRNA expression level of STAT5 was downregulated by AIU2001 treatment and knockdown of STAT5 inhibited the DNA repair genes. Our results show that compared to either drug alone, the combination of AIU2001 with a poly (ADP-ribose) polymerase (PARP) inhibitor olaparib or irradiation showed synergistic efficacy in H1299 and A549 cells. Hence, our findings demonstrate that AIU2001 is a candidate therapeutic agent for NSCLC and combination therapies with AIU2001 and a PARP inhibitor or radiotherapy may be used to increase the therapeutic efficacy of AIU2001 due to inhibition of DNA damage repair.
format Online
Article
Text
id pubmed-6801739
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-68017392019-10-31 Antitumor Activity of a Novel Tyrosine Kinase Inhibitor AIU2001 Due to Abrogation of the DNA Damage Repair in Non-Small Cell Lung Cancer Cells Ryu, Hwani Choi, Hyun-Kyung Kim, Hyo Jeong Kim, Ah-Young Song, Jie-Young Hwang, Sang-Gu Kim, Jae-Sung Kim, Da-Un Kim, Eun-Ho Kim, Joon Ahn, Jiyeon Int J Mol Sci Article Class III receptor tyrosine kinase (RTK) inhibitors targeting mainly FLT3 or c-KIT have not been well studied in lung cancer. To identify a small molecule potentially targeting class III RTK, we synthesized novel small molecule compounds and identified 5-(4-bromophenyl)-N-(naphthalen-1-yl) oxazol-2-amine (AIU2001) as a novel class III RKT inhibitor. In an in vitro kinase profiling assay, AIU2001 inhibited the activities of FLT3, mutated FLT3, FLT4, and c-KIT of class III RTK, and the proliferation of NSCLC cells in vitro and in vivo. AIU2001 induced DNA damage, reactive oxygen species (ROS) generation, and cell cycle arrest in the G2/M phase. Furthermore, AIU2001 suppressed the DNA damage repair genes, resulting in the ‘BRCAness’/‘DNA-PKness’ phenotype. The mRNA expression level of STAT5 was downregulated by AIU2001 treatment and knockdown of STAT5 inhibited the DNA repair genes. Our results show that compared to either drug alone, the combination of AIU2001 with a poly (ADP-ribose) polymerase (PARP) inhibitor olaparib or irradiation showed synergistic efficacy in H1299 and A549 cells. Hence, our findings demonstrate that AIU2001 is a candidate therapeutic agent for NSCLC and combination therapies with AIU2001 and a PARP inhibitor or radiotherapy may be used to increase the therapeutic efficacy of AIU2001 due to inhibition of DNA damage repair. MDPI 2019-09-24 /pmc/articles/PMC6801739/ /pubmed/31554189 http://dx.doi.org/10.3390/ijms20194728 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Ryu, Hwani
Choi, Hyun-Kyung
Kim, Hyo Jeong
Kim, Ah-Young
Song, Jie-Young
Hwang, Sang-Gu
Kim, Jae-Sung
Kim, Da-Un
Kim, Eun-Ho
Kim, Joon
Ahn, Jiyeon
Antitumor Activity of a Novel Tyrosine Kinase Inhibitor AIU2001 Due to Abrogation of the DNA Damage Repair in Non-Small Cell Lung Cancer Cells
title Antitumor Activity of a Novel Tyrosine Kinase Inhibitor AIU2001 Due to Abrogation of the DNA Damage Repair in Non-Small Cell Lung Cancer Cells
title_full Antitumor Activity of a Novel Tyrosine Kinase Inhibitor AIU2001 Due to Abrogation of the DNA Damage Repair in Non-Small Cell Lung Cancer Cells
title_fullStr Antitumor Activity of a Novel Tyrosine Kinase Inhibitor AIU2001 Due to Abrogation of the DNA Damage Repair in Non-Small Cell Lung Cancer Cells
title_full_unstemmed Antitumor Activity of a Novel Tyrosine Kinase Inhibitor AIU2001 Due to Abrogation of the DNA Damage Repair in Non-Small Cell Lung Cancer Cells
title_short Antitumor Activity of a Novel Tyrosine Kinase Inhibitor AIU2001 Due to Abrogation of the DNA Damage Repair in Non-Small Cell Lung Cancer Cells
title_sort antitumor activity of a novel tyrosine kinase inhibitor aiu2001 due to abrogation of the dna damage repair in non-small cell lung cancer cells
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6801739/
https://www.ncbi.nlm.nih.gov/pubmed/31554189
http://dx.doi.org/10.3390/ijms20194728
work_keys_str_mv AT ryuhwani antitumoractivityofanoveltyrosinekinaseinhibitoraiu2001duetoabrogationofthednadamagerepairinnonsmallcelllungcancercells
AT choihyunkyung antitumoractivityofanoveltyrosinekinaseinhibitoraiu2001duetoabrogationofthednadamagerepairinnonsmallcelllungcancercells
AT kimhyojeong antitumoractivityofanoveltyrosinekinaseinhibitoraiu2001duetoabrogationofthednadamagerepairinnonsmallcelllungcancercells
AT kimahyoung antitumoractivityofanoveltyrosinekinaseinhibitoraiu2001duetoabrogationofthednadamagerepairinnonsmallcelllungcancercells
AT songjieyoung antitumoractivityofanoveltyrosinekinaseinhibitoraiu2001duetoabrogationofthednadamagerepairinnonsmallcelllungcancercells
AT hwangsanggu antitumoractivityofanoveltyrosinekinaseinhibitoraiu2001duetoabrogationofthednadamagerepairinnonsmallcelllungcancercells
AT kimjaesung antitumoractivityofanoveltyrosinekinaseinhibitoraiu2001duetoabrogationofthednadamagerepairinnonsmallcelllungcancercells
AT kimdaun antitumoractivityofanoveltyrosinekinaseinhibitoraiu2001duetoabrogationofthednadamagerepairinnonsmallcelllungcancercells
AT kimeunho antitumoractivityofanoveltyrosinekinaseinhibitoraiu2001duetoabrogationofthednadamagerepairinnonsmallcelllungcancercells
AT kimjoon antitumoractivityofanoveltyrosinekinaseinhibitoraiu2001duetoabrogationofthednadamagerepairinnonsmallcelllungcancercells
AT ahnjiyeon antitumoractivityofanoveltyrosinekinaseinhibitoraiu2001duetoabrogationofthednadamagerepairinnonsmallcelllungcancercells